ENTITY
SK Biopharmaceuticals

SK Biopharmaceuticals (326030 KS)

154
Analysis
Health CareSouth Korea
SK Biopharmaceuticals Co., Ltd. researches and develops new drugs. The Company develops and markets brain disorders treatment drugs, central nervous system disorders treatment drugs, and other products. SK Biopharmaceuticals markets its products worldwide.
more
01 Jul 2020 06:11

Korea Stock Market Monthly Recap #49 (June 2020)

Review of Top 10 Issues Related to Korean stock market, economy, & politics in June 2020: SK Biopharm IPO SK Holdings downgrade Capital gains...

Logo
467 Views
Share
bearishSK Inc
25 Jun 2020 07:40

KB Bank Sells 2.5% Stake in SK Holdings in a Block Deal

Yesterday, KB Kookmin Bank sold about 2.5% of its stake in SK Holdings (034730 KS) for about 500 billion won in a "club deal basis" to foreign...

Logo
427 Views
Share
24 Jun 2020 08:54

KOSPI200 Index Rebalance Preview - Positioning Begins for December

The Korea Exchange (KRX) will announce the results of the December 2020 review of the Korea Stock Exchange Kospi 200 Index (KOSPI2 INDEX) in...

Logo
936 Views
Share
19 Jun 2020 22:01

SK Biopharmaceuticals IPO Book-Building Results & Ramifications

Yes, it is a new record. The competition rate is 836 to 1, which is the highest among the ₩500bil+ IPOs in Korea. The previous record-holder was...

Logo
508 Views
Share
19 Jun 2020 21:54

Trading Strategy for SK Biopharm Post IPO Pricing

SK Biopharm announced its stellar IPO book building results today. The IPO price has been confirmed at 49,000 won, which is at the high end of the...

Logo
569 Views
Share
x